===Healthpeak Properties (DOC) reported earnings on Tue 5 May 26 (a/h)

 

Healthpeak Properties beats by $0.02, beats on revs; guides FY26 FFO in-line

• Reports Q1 (Mar) funds from operations of $0.45 per share, excluding non-recurring items, $0.02 better than the FactSet Consensus of $0.43; revenues rose 7.1% year/year to $752.9 mln vs the $694.59 mln FactSet Consensus.
• In March 2026, Janus Living, Inc. (JAN) completed its initial public offering at the high-end of the valuation range, generating approximately $880 million of net proceeds in an oversubscribed and upsized offering, to pursue accretive acquisition and investment opportunities.
• JAN reported post-IPO net loss of $(0.05) per share, first quarter net income of $0.13 per share and first quarter FFO as Adjusted of $0.23 per share.
• Co issues in-line guidance for FY26, sees FFO of $1.71-$1.75, excluding non-recurring items, vs. $1.73 FactSet Consensus.

Long trade : HIMX +27% (12/24)

 a) Mon March 9: #4; vol. 1.0M

March 10:  #3, 23; vol. 2.6M

 

Hunterbrook Media report claiming Himax as stealth NVIDIA optics supplier drove premarket surge.

A Hunterbrook Media article titled "Himax: Stealth Supplier for NVIDIA’s Optics Revolution" highlighted the company's potential role in providing wafer-level optics (WLO) for NVIDIA's AI-related silicon photonics and advanced packaging needs, building on prior analyst notes from Ming-Chi Kuo about Himax supplying micro-lens arrays for TSMC/NVIDIA projects. Published ahead of market open, it triggered heavy premarket buying, with shares jumping over 25% amid elevated volume and call option activity from the prior session. Hunterbrook Capital disclosed a long position in HIMX, contrasting it favorably against peers like AAOI facing negative coverage. This amplified recent buzz from Himax's March 9 announcement of AIoT and automotive tech showcases at Embedded World 2026 (March 10-12).

Papa John's (PZZA) : Irth Capital's $47-per-share takeover bid

 a. Mon 3/9/26:  #4; vol. 2.0M

 

A Wall Street Journal article, citing sources familiar with the matter, revealed that Qatari-backed Irth Capital Management—recently building a nearly 10% stake—submitted a bid to acquire the company at $47 per share, valuing it at approximately $1.5 billion with backing from Brookfield Asset Management. This represented a roughly 50% premium to the prior trading price around $31-32. Shares jumped nearly 19%, triggering a trading halt amid heightened volume, as investors reacted to revived M&A prospects following prior unmaterialized offers.

The move follows Irth’s attempt last year to buy Papa John’s alongside private-equity firm Apollo Global Management, though the talks ended without an agreement.

Irth was created in 2024 as a global asset manager. Headed by co-founders Sheikh Mohamed bin Abdulla Al-Thani and Matthew Bradshaw, it is supported by a member of the Qatari royal family.

A potential acquisition of Papa John’s would rank among Irth’s first major moves.

Viant Technology (DSP) reported earnings on Wed 11 March 26 (a/h)

Viant was launched by brothers Tim, Chris and Russ Vanderhook in 1999. The company acquired social networking company Myspace in 2011. Later that year it helped start connected TV platform Xumo, which was acquired by Comcast in 2020.

• Sector: Technology
• Industry: Software - Application
• https://www.viantinc.com
• Founded in 1999
• Headquartered in Irvine, CA

IPO Feb 10, 21; ticker DSP 

Chris and Tim Vanderhook, COO and CEO of Viant

Viant posts record Q4 2025 with EPS $0.31 (+210% YoY) and revenue $64.6M (+19% YoY), beating guidance and estimates, launches AI Outcomes product

• Q4 revenue and contribution ex-TAC beat guidance, with ex-political growth accelerating sharply.
• Full-year 2025 revenue and adjusted EBITDA exceeded guidance with high-teens growth and nearly 250 bps EBITDA margin expansion.
• Upbeat Q1 2026 guide implies ~20% revenue growth but slower Q4-like momentum seasonally.
• Management expects sequential growth acceleration through 2026 from new clients, Outcomes, and political.

The company, which has about 300 employees, competes with players like The Trade Desk and with part of Google’s ad tech business. The software is used by marketers and their ad agencies to centralize buying, planning and measurement of advertising across channels like desktop, mobile, connected TV, streaming audio and digital billboards.

Ero Copper (ERO) +17%

Ero Copper Corp. engages in the exploration, development, and production of mining projects in Brazil. 

Its flagship asset includes Caraíba operations that comprise the production and sale of copper concentrates located in northeastern Bahia State, Brazil, as well as gold and silver produced and sold as by-products. 

• Sector: Basic Materials
• Industry: Copper
• Full Time Employees: 3,690
• Incorporated in 2016 
• Headquartered in Vancouver, Canada
• https://erocopper.com

Porch Group (PRCH) reported earnings on 6 May 25 (a/h)

The Seattle-based home services technology company Porch Group went public on December 24, 2020, following a merger with the special purpose acquisition company (SPAC) PropTech Acquisition Corp., and a private investment from Wellington Management Company.

• Its shares began trading on the Nasdaq under the ticker symbol PRCH.

Porch CEO and founder Matt Ehrlichman

Porch Group went public on December 24, 2020

Black Rifle Coffee Co. (BRCC) reported earnings on Mon 5 May 25 (a/h)

BRC Inc. operates as a veteran-controlled, non-alcoholic beverage company that uniquely blends high-quality coffee production with military and firearms-themed merchandise.

• Sector: Consumer Defensive
• Industry: Packaged Foods
• Full Time Employees: 551
• Founded in 2014 
• HQ in Salt Lake City, Utah
• https://www.blackriflecoffee.com

IPO: February 10, 2022 via a merger with a special purpose acquisition company, or SPAC, affiliate of SilverBox Capital

 ** charts after earnings **

SALT LAKE CITY--(BUSINESS WIRE)--BRC Inc. (NYSE: BRCC), a Veteran-founded, mission-driven premium beverage company, today announced financial results for the first quarter of fiscal year 2025.

• In Q1 2025, packaged coffee distribution increased by 12.2 percentage points to 50.2% ACV and Ready-to-Drink ("RTD") coffee distribution grew by 5.1 percentage points to 47.9% ACV compared to Q1 2024.
• Wholesale revenue declined 6.0% compared to Q1 2024, primarily due to the net reduction of $8.5 million in prior-year barter transaction revenue.
• Net loss was $7.8 million in Q1 2025, a decrease of $9.7 million compared to net income of $1.9 million in Q1 2024. Adjusted EBITDA was $0.9 million, down $11.6 million from $12.5 million in Q1 2024.

AirSculpt Technologies (AIRS) reported earnings on Fri 2 May 25 (b/o)

 ** charts after earnings **

 

 

First Quarter 2025 Results

• Case volume was 3,076 for the first quarter of 2025, representing a 17.9% decline from the fiscal year 2024 first quarter case volume of 3,746;
• Revenue declined 17.3% to $39.4 million from $47.6 million in the fiscal year 2024 first quarter;
• Net loss for the quarter was $2.8 million compared to net income of $6.0 million in the fiscal year 2024 first quarter; and Adjusted EBITDA was $3.8 million compared to $7.3 million for the fiscal year 2024 first quarter.

2025 Outlook

The Company projects full year 2025 revenue and adjusted EBITDA guidance as follows:

• Revenues of approximately $160 to $170 million
• Adjusted EBITDA of approximately $16 to $18 million

MeiraGTx (MGTX) $200M deal with Hologen AI for Parkinson's therapy

 

 

 

 

 

 

IPO: June 8, 2018

Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy through phase 3 and beyond

MeiraGTx will partner with Hologen AI to leverage its multimodal generative AI (genAI) models to accelerate Phase III development of the biotech's AAV-GAD gene therapy for Parkinson’s disease. 

The therapy, dubbed AAV-GAD, delivers a gene that codes for the enzyme that makes the neurotransmitter GABA, which is implicated in the characteristic motor dysfunction of Parkinson’s. A small-scale phase 2 readout last October showed that AAV-GAD was able to improve patients' motor ability and quality of life.

Details of the agreement 

MeiraGTx will receive an upfront cash payment of $200 million from Hologen, and together, the partners will launch a joint venture called Hologen Neuro AI. The genAI firm will also contribute $230 million in funding for the JV, which will shepherd AAV-GAD through development to commercialisation. The capital will help support other early-stage clinical programmes targeting the central nervous system (CNS), such as AAV-BDNF for genetic obesity. 

MeiraGTx will retain 30% ownership in Hologen Neuro AI and take the lead on all clinical development and manufacturing. It will form exclusive clinical and commercial manufacturing supply agreements with the JV. 

In turn, Hologen will use its genAI tech to optimise MeiraGTx's manufacturing practices, while gaining a minority stake in the manufacturing subsidiary and contributing to annual funding. 

About Hologen 

Hologen Limited is a world-leading developer of generative AI capabilities for clinical medicine and pharmaceutical drug development. 

The company emerged as a spin-out from University College London and Kings College London. It is privately held.

For more information, please visit www.hologen.ai

===ADT (ADT ) reported earnings on Thur 27 Feb 25 (b/o)

 

 ADT reports EPS in-line, beats on revs; guides FY25 EPS in-line, revs in-line; announces new $500 mln share repurchase plan

• Reports Q4 (Dec) earnings of $0.20 per share, excluding non-recurring items, in-line with the two analyst estimate of $0.20; revenues rose 7.5% year/year to $1.26 bln vs the $1.23 bln single analyst estimate.
• Co issues in-line guidance for FY25, sees EPS of $0.77-0.85, excluding non-recurring items, vs. $0.81 two analyst estimate; sees FY25 revs of $5.025-5.225 bln vs. $5.04 bln two analyst estimate.
• On Feb. 27, 2025, the Company's Board of Directors announced a share repurchase plan. pursuant to which the Company is authorized to repurchase, through April 30, 2026, up to a maximum aggregate amount of $500 million of shares of Common Stock.

GeneDx (WGS) reported earnings on Tue 18 Feb 25 (b/o)

** charts after earnings ** 

Strong Beat, Guidance: This provider of exome and genome tests is a play on the shift toward personalized medicine and earlier intervention.

During the fourth quarter, GeneDx earned an adjusted 77 cents per share, obliterating forecasts for 16 cents, according to FactSet. Earnings flipped from a year-earlier loss of 49 cents. Sales grew almost 65% to $95.6 million, well ahead of calls for $82.2 million.

GeneDx also guided to $350 million to $360 million in full-year sales. The low end of the outlook easily beat analysts' forecast for $340.4 million.

GeneDx uses AI to provide genomics-related diagnostic testing.

GeneDx provides whole genome and exome sequencing to help identify rare diseases, primarily in children. The genome includes all the DNA in the body, while reading the exome involves looking at only the protein-coding genes.

When performed early, genetic testing can lead to answers that help avoid what Chief Executive Katherine Stueland calls a "diagnostic odyssey." The company only tests for diseases where there is a solution — a clinical study, a dietary change or a treatment.

Absci (ABSI) : 4-year performance

 

 

Long trade : REKR +20% (12/24)

 

Absci (ABSI) : 3-year performance

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 140
• Founded by Sean McClain in 2011 
• Headquartered in Vancouver, Washington
• https://www.absci.com

IPO: July 22, 2021; shares priced at $16

Ticker: ABSI 

 

 

 

 

 

===Protara Therapeutics (TARA) : Positive results from Phase 2 ADVANCED-2 trial of TARA-002 in patients with NMIBC

• TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures
• 100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients
• 64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients
• 80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposures
• Favorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse events

 

Company Profile

• Protara Therapeutics
• Industry: Health Care
• Website: https://artaratx.com/

===Esperion Therapeutics (ESPR) : new drug submissions in Canada for NEXLETOL treatments

Co announced that it has filed New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications that reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk.

 

Ecovyst (ECVT) reported earnings on Thur 31 Oct 24 (b/o)

The company was formerly known as PQ Group Holdings Inc. and changed its name to Ecovyst Inc. in August 2021.

• Sector(s): Basic Materials
• Industry: Specialty Chemicals
• Full Time Employees: 911
• Founded in 1831 
• Headquartered in Malvern, Pennsylvania
• https://www.ecovyst.com

** charts 1 day after earnings **